title: Drug-related problems and the clinical role of pharmacists in inpatient mental health: an insight into practice in Australia.
abstract: BACKGROUND
  Drug-related problems (DRPs) cause significant morbidity and mortality in healthcare. Clinical pharmacists have shown to reduce DRPs in the inpatient setting. In mental health the effects of clinical pharmacists on DRPs is relatively unknown.
  
  
  OBJECTIVE
  To explore the clinical role of inpatient mental health pharmacists and the factors affecting their role.
  
  
  METHODS
  Australian hospitals.
  
  
  METHODS
  Mixed methods. As the profile of the hospital mental health pharmacy workforce is unknown, surveys were distributed to all Australian hospitals with a pharmacy department. DRPs and recommendations were classified using an adaptation of the DOCUMENT system. In-depth semi-structured interviews were undertaken with members of the Society of Hospital Pharmacists Australia's Mental Health Committee of Specialty Practice.
  
  
  METHODS
  Types of DRPs identified by mental health pharmacists, the recommendations made to address them and the rate at which these recommendations were implemented. As well as mental health pharmacists' views on the factors which affect their clinical role.
  
  
  RESULTS
  277 clinical interventions were reported by 47 mental health pharmacists, with 332 DRPs identified and 355 recommendations made. Drug interactions were the most commonly identified DRP (13.9 %). DRPs ranged in severity and likelihood of occurring. Changes to therapy accounted for the vast majority of recommendations (60.8 %), with the most common being change of drug (29.9 %). In total 91.8 % of recommendations were implemented. On average pharmacists estimated 56.1 % of their clinical interventions focused on psychotropic medication issues. Sixteen pharmacists were interviewed. Their relationship with the medical officers, time constraints and a gap in the evidence base to guide practice were identified as the major factors affecting their role.
  
  
  CONCLUSIONS
  Pharmacists play an important role in ensuring the quality use of medicines in inpatient mental health. However, significant factors need to be addressed to further expand clinical pharmacy services in inpatient mental healthcare in Australia.
authors.affiliation: Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia, tric6553@uni.sydney.edu.au.
authors.forename: Tom E
authors.initials: TE
authors.lastname: Richardson
authors.forename: Claire L
authors.initials: CL
authors.lastname: O'Reilly
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Chen
mesh_terms: D001291:Attitude of Health Personnel; D001315:Australia; D003430:Cross-Sectional Studies; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D006801:Humans; D007297:Inpatients / Q000523:psychology*; D001523:Mental Disorders / Q000188:drug therapy; D010595:Pharmacists / Q000523:psychology / Q000706:statistics & numerical data*; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data*; D024382:Professional Role
references.citation: Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S16-26
references.pmid: 15052511
references.citation: Am J Pharm Educ. 2010 Nov 10;74(9):163
references.pmid: 21301597
references.citation: Int J Clin Pharm. 2012 Feb;34(1):43-52
references.pmid: 22101425
references.citation: Aust N Z J Psychiatry. 2011 Nov;45(11):993-1001
references.pmid: 21999241
references.citation: Arch Gen Psychiatry. 1976 Jun;33(6):766-71
references.pmid: 938196
references.citation: J Clin Pharm Ther. 1996 Feb;21(1):45-8
references.pmid: 8737183
references.citation: Schizophr Bull. 1998;24(1):11-20; discussion 20-32
references.pmid: 9502543
references.citation: Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S121-8
references.pmid: 18346600
references.citation: Am J Pharm Educ. 2011 Feb 10;75(1):8
references.pmid: 21451760
references.citation: JAMA. 1997 Jan 22-29;277(4):307-11
references.pmid: 9002493
references.citation: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005470
references.pmid: 20238340
references.citation: Br J Psychiatry. 2000 Sep;177:212-7
references.pmid: 11040880
references.citation: Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1139-54
references.pmid: 22761169
references.citation: Arch Intern Med. 2006 May 8;166(9):955-64
references.pmid: 16682568
references.citation: Pharmacotherapy. 2000 May;20(5):583-8
references.pmid: 10809346
references.citation: J Am Pharm Assoc (2003). 2011 Sep-Oct;51(5):599-604
references.pmid: 21896457
references.citation: J Manag Care Pharm. 2013 Jun;19(5):408-16
references.pmid: 23697478
references.citation: BMJ. 2013 May 21;346:f2539
references.pmid: 23694688
references.citation: Ann Pharmacother. 2008 Jul;42(7):1017-25
references.pmid: 18594048
references.citation: J Interprof Care. 2009 Mar;23(2):169-84
references.pmid: 19234987
references.citation: Br J Clin Pharmacol. 2004 Apr;57(4):513-21
references.pmid: 15025751
references.citation: Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S39-45
references.pmid: 15052513
references.citation: World Psychiatry. 2011 Jun;10(2):138-51
references.pmid: 21633691
references.citation: Ann Pharmacother. 2006 Sep;40(9):1623-34
references.pmid: 16912249
references.citation: Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):989-94
references.pmid: 16343299
references.citation: Int J Clin Pharm. 2014 Apr;36(2):222-32
references.pmid: 24306436
references.citation: J Clin Pharm Ther. 1997 Feb;22(1):27-31
references.pmid: 9292399
references.citation: Arch Intern Med. 2003 Sep 22;163(17):2014-8
references.pmid: 14504113
references.citation: JAMA. 1999 Jul 21;282(3):267-70
references.pmid: 10422996
references.citation: Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72
references.pmid: 14960256
references.citation: Qual Saf Health Care. 2008 Jun;17(3):216-23
references.pmid: 18519629
references.citation: Lancet. 2009 Aug 22;374(9690):620-7
references.pmid: 19595447